Related Experiment Video
Updated: May 6, 2026
15:17
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
13.4K
Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer
Heather P Ostendorff1, Amany Awad, Karen I Braunschweiger
1AmberGen, Inc., 313 Pleasant Street, Watertown, MA 02472, USA.
Journal of Immunological Methods
|October 29, 2013
Summary
A novel blood test using multiplexed protein biomarkers shows promise for non-invasive colorectal cancer (CRC) screening. This assay could significantly improve early detection and complement existing screening methods.
Area of Science:
- Biomarker discovery and assay development
- Molecular diagnostics
- Cancer research
Background:
- Colorectal cancer (CRC) remains a leading cause of cancer death, necessitating improved screening methods.
- Current screening methods like colonoscopy are invasive and have low throughput.
- Blood-based protein biomarkers offer potential for non-invasive early diagnosis, but robust multiplexing platforms are needed.
Purpose of the Study:
- To develop a novel, multiplexed, hybrid immunoassay for colorectal cancer (CRC) detection.
- To adapt the VeraCode™ micro-bead platform, typically used for genomic assays, for proteomic biomarker analysis.
- To evaluate the assay's performance in detecting CRC using serum samples.
Main Methods:
- Development of a hybrid immunoassay combining sandwich immunoassay for serum proteins (CEA, GDF15) and antigen assay for autoantibodies (anti-p53 TAA).
- Formatting the assay on barcoded VeraCode™ micro-beads for multiplexed detection.
- Utilizing Illumina's micro-bead platform for high-throughput analysis of small blood volumes (<50 μL).
Main Results:
- The multiplex biomarker panel was successfully configured on the VeraCode™ platform.
- In an initial evaluation with 186 patient sera, the assay achieved a diagnostic sensitivity of 54% and a specificity of 98%.
- The assay demonstrated potential for low-volume, high-throughput multiplexed analysis.
Conclusions:
- The novel hybrid immunoassay on the VeraCode™ platform represents a promising approach for colorectal cancer (CRC) biomarker validation, screening, and diagnostics.
- Further refinement of biomarkers and extensive clinical validation are anticipated to establish this assay for population screening.
- This non-invasive assay could complement existing screening modalities, addressing the need for effective early detection of CRC.
